Telephone
61.2.9805.0488
Address
Suite 3.3 56 Delhi Road North Ryde, New South Wales (NSW) 2113
Description
Biotron Ltd. engages in the funding and management of research, development, and commercialization of drugs targeting significant viral diseases. It is developing the compound BIT225 for the treatment of HIV-1. The company was founded in February 1999 and is headquartered in North Ryde, Australia.
Market Cap
PE
EV/EBITDA
DIV Yield
Franking
Ex Dividend Date (est.)
52 weeks range
Low 0.02 - 0.12
Trade Value (12mth)
AU$49,039.00
1 week
-9.18%
1 month
-11%
YTD
206.9%
1 year
229.63%
All time high
0.430968
EPS 3 yr Growth
-18.900%
EBITDA Margin
N/A
Operating Cashflow
-$3m
Free Cash Flow Return
-152.50%
ROIC
-161.90%
Interest Coverage
-1,138.20
Quick Ratio
4.20
Shares on Issue (Fully Dilluted)
902m
HALO Sector
Healthcare
Next Company Report Date
29-Aug-24
Ex Dividend Date (est.)
N/A
Next Dividend Pay Date (est.)
N/A
Reporting Currency
AUD
Short Sell (% of issue)
0.00
Date | Announcements |
---|---|
31 October 22 |
Letter to Shareholders
×
Letter to Shareholders |
31 October 22 |
Commencement of Rights Trading - BITRC
×
Commencement of Rights Trading - BITRC |
31 October 19 |
Presentation to Investors
×
Presentation to Investors |
31 October 06 |
Anti-HCV Compound Presentation to International Conference
×
Anti-HCV Compound Presentation to International Conference |
31 March 11 |
Presentation to Investors
×
Presentation to Investors |
31 January 23 |
Quarterly Activities/Appendix 4C Cash Flow Report
×
Quarterly Activities/Appendix 4C Cash Flow Report |
30 May 22 |
POSITIVE FDA GUIDANCE FOR COVID-19 CLINICAL PROGRAM
×
POSITIVE FDA GUIDANCE FOR COVID-19 CLINICAL PROGRAM |
30 May 13 |
PRESENTATION OF HIV DATA AT INTERNATIONAL AIDS SOCIETY
×
PRESENTATION OF HIV DATA AT INTERNATIONAL AIDS SOCIETY |
29 September 23 |
Response to ASX Price Query
×
Response to ASX Price Query |
29 September 09 |
Annual Report and Notice of AGM
×
Annual Report and Notice of AGM |
29 November 22 |
Change of Director's Interest Notice
×
Change of Director's Interest Notice |
28 October 13 |
Biotron to Present at Australia Biotech Invest 2013
×
Biotron to Present at Australia Biotech Invest 2013 |
28 November 22 |
Notification of cessation of securities - BIT
×
Notification of cessation of securities - BIT |
28 November 18 |
PRESENTATION OF BIT225-009 HIV-1 PHASE 2 DATA
×
PRESENTATION OF BIT225-009 HIV-1 PHASE 2 DATA |
28 November 12 |
Chairman\'s Address and Presentation to the AGM
×
Chairman\'s Address and Presentation to the AGM |
28 May 15 |
Presentation to Investors
×
Presentation to Investors |
28 July 23 |
Quarterly Activities/Appendix 4C Cash Flow Report
×
Quarterly Activities/Appendix 4C Cash Flow Report |
28 July 22 |
Quarterly Activities/Appendix 4C Cash Flow Report
×
Quarterly Activities/Appendix 4C Cash Flow Report |
28 January 22 |
Quarterly Appendix 4C Cash Flow Report
×
Quarterly Appendix 4C Cash Flow Report |
28 January 22 |
Quarterly Activities/Appendix 4C Cash Flow Report
×
Quarterly Activities/Appendix 4C Cash Flow Report |
28 August 15 |
Annual Report to Shareholders
×
Annual Report to Shareholders |
28 August 14 |
Annual Report to Shareholders
×
Annual Report to Shareholders |
28 August 13 |
Annual Report to shareholders
×
Annual Report to shareholders |
27 October 23 |
Quarterly Activities/Appendix 4C Cash Flow Report
×
Quarterly Activities/Appendix 4C Cash Flow Report |
27 October 22 |
Proposed issue of securities - BIT
×
Proposed issue of securities - BIT |
27 October 22 |
Renounceable Issue
×
Renounceable Issue |
27 October 22 |
Prospectus
×
Prospectus |
Load More
Load Less
Historical data
Forecasted data
Load More
Load Less
Historical data
Forecasted data
Load More
Load Less
Historical data
Forecasted data
Load More
Load Less
Percent of Issue
Value ($M)
Prior Change
7 Day Change
1 Month Change
3 Month Change
Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.
Unlock true investor intelligence
Research, trade and manage global markets from one place with HALO Global. It’s trading - the way you want it.
Get the latest insights and hot tips delivered right to your inbox
HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.